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Adequate asthma treatment of childhood exacerbations with IV aminophylline depends on
appropriate dosage. Recommendations to aim for a target therapeutic range may be inap-
propriate as serum concentrations correlate poorly with clinical improvement. This review
aims to evaluate the evidence for the optimum dosage strategy of intravenous aminophyl-
line in children suffering an exacerbation of asthma.
Methods
A systematic review comparing dosage regimens of intravenous aminophylline in children
suffering an exacerbation of asthma. Primary outcomes were time until resolution of symp-
toms, mortality and need for mechanical ventilation. Secondary outcomes were date until
discharge criteria are met, actual discharge and adverse effects.
Data sources
CENTRAL, CINAHL, MEDLINE andWeb of Science. Search performed in March 2016
Eligibility criteria
Studies using intravenous aminophylline in children with an acute exacerbation of asthma
which reported the dosage and clinical outcomes.
Findings
14 RCTs were included. There is a poor relationship between the dosage administered to
children and symptom resolution, length of stay or need for mechanical ventilation. This
study is limited due to its use of indirect evidence.
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Conclusion
The currently recommended dosage regimens may not represent the optimum safety and
efficacy of intravenous aminophylline. There is a need to develop the evidence base corre-
lating dosage with patient centered clinical outcomes, to improve prescribing practices.
Introduction
Intravenous aminophylline can be used to manage exacerbations of asthma in children who do
not respond to first line inhaled/nebulised therapy [1]. Accurate dosing is important, to ensure
adequate asthma treatment, whilst reducing toxicity [2–4].
Aminophylline has a widely accepted therapeutic range of 10-20mg/l, which drives dosing
decisions in children [1,5]. Current intravenous loading doses of between 5-6mg/kg are used to
achieve levels within this range [6,7], although this is not regularly achieved in routine clinical
practice [8–10]. Aiming for a target serum concentration of aminophylline is complicated by
its high interindividual variation in clearance rates [11], the reasons for which are poorly
understood [12–14]. It is not clear whether recommended adjustments of aminophylline dos-
age based on age, weight, and previous serum drug concentrations [5] optimise its efficacy and
safety.
The treatment of acute asthma in children should be guided by evidence of improvement of
clinically relevant outcomes [15,16]. A recent systematic review found no evidence to support
improved efficacy of aminophylline once the serum concentration increases above the lower
threshold of 10mg/L, nor increased toxicity at levels above 20mg/l [17]. As the current thera-
peutic range is a poor guide to efficacy, an alternative dosing strategy may improve the opti-
mum efficacy and safety profile of aminophylline. This systematic review aims to evaluate the




We conducted a systematic review of studies utilizing intravenous theophyllines in the man-
agement of asthma exacerbations in children.
Included studies
Few studies primarily investigate the optimum dosing strategies in children [18] Therefore, we
used a systematic review technique which anticipates various study designs, similar to the
methodology we recently used to examine the evidence around therapeutic ranges for ami-
nophylline [17,19]. We decided a priori that the most relevant study type would be a compari-
son of randomised controlled trials (RCTs) comparing different dosing strategies and
measuring clinically relevant outcomes, but we would also include RCTs evaluating the efficacy
of intravenous theophyllines compared with placebo or other treatment, with subsequent anal-
yses performed for each comparator drug, and observational studies.
We included studies that investigate the efficacy of intravenous theophyllines in children
suffering an exacerbation of asthma if the dosing regimen was reported. We excluded studies
performed in adults, those utilizing theophyllines for indications other than asthma or studies
using non-intravenous routes.
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Outcomes
The pre-specified primary outcomes were time until resolution of symptoms, need for mechan-
ical ventilation, and mortality. Secondary outcomes were the number of days until discharge
criteria are met, number of days until actual discharge from hospital and adverse effects as
defined and reported by authors.
Identification of studies
The following search strategy was used to search MEDLINE, CINAHL andWeb of Science in
March 2016 with no date or language restrictions. The Cochrane Central Register of Controlled
Trials was also searched for gray literature asthma AND (emerg OR acute OR severe OR
intensive OR exacerbation OR critical OR refractory OR hospitalied OR attack OR status)
AND (aminophylline OR intravenous theophylline OR xanthin ORmethylxanthin) AND
(child OR adolescent OR infan OR pediatric)
Reviewer LC screened titles and abstracts, a second reviewer (IS or DH) checked the eligibil-
ity of abstracts after initial screening, and full studies included in the review. Reference lists
were screened for other eligible studies.
Data extraction and analysis
From each study we extracted the loading dose and/or maintenance dose of IV theophyllines
administered, and whether subsequent doses were adjusted based on the results of therapeutic
drug monitoring. The age range, number of participants and use of concomitant medications
was also extracted.
Statistical analysis. We intended to conduct a quantitative synthesis by pooling studies
utilizing similar dosing regimens using REVMAN (http://tech.cochrane.org/revman). Separate
meta analyses for each dosing regimen used would allow for a quantitative comparison of effect
size between studies using random effects modeling. If quantitate techniques were not possible
due to methodological or reporting heterogeneity, or insufficient data, we planned for a
descriptive analysis correlating pre-specified clinical outcomes to the dosing strategies used.
Assessment of risk of bias. The Cochrane Risk of Bias Tool was applied to each RCT to
help determine the validity of results.
Results
Our search strategy returned 1764 studies, with 38 full text articles assessed for eligibility. We
excluded 23 full text articles (S1 File) with the remaining 14 studies included in this systematic
review (Fig 1).
No RCTs comparing dosing strategies for IV aminophylline in children suffering an exacer-
bation of asthma were identified. We therefore included 14 RCTs comparing aminophylline to
placebo (n = 10) or β2 adrenergic agonists (n = 4).
Risk of Bias of Included Studies
The results from the Cochrane risk of bias assessment are shown in Fig 2. A high risk of selec-
tion bias was found in one study [20], performance bias was found in two studies [21,22], attri-
tion bias in six studies [21,23–27] and reporting bias in two studies [23,28]. All other domains
were found to have a low or unclear risk of bias.
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Clinical outcomes of studies using IV theophyllines for an acute
exacerbation of asthma.
Studies were grouped based on whether they compared aminophylline to placebo or β2 adren-
ergic agonist. The loading doses, maintenance doses and clinical outcomes are shown in Tables
1 and 2.
Doses of aminophylline given
The doses given to children across RCTs utilizing IV aminophylline for an acute exacerbation
of asthma in children is highly variable. All but one study [31] prescribes aminophylline as a
loading dose followed by an infusion. All studies calculate doses based on the weight of individ-
ual participants. Loading doses range from 4-10mg/kg and infusion rates range from 0.5–
1.2mg/kg/hr.
Age was factored into dosing strategies of aminophylline in eight studies. Age influenced
both the loading dose and the infusion rate given in one study [21], with the remaining seven
Fig 1. Search results.
doi:10.1371/journal.pone.0159965.g001
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Fig 2. Results of assessment of risk of bias.Green–Low risk of bias, Red–High risk of bias, Amber–
Unclear risk of bias.
doi:10.1371/journal.pone.0159965.g002
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studies using age adjusted maintenance doses only [22–26,30,31]. In most studies, younger
patients received higher doses of IV aminophylline.
The results of therapeutic drug monitoring (TDM) factored into aminophylline dosage cal-
culations in the majority of studies. Infusion rates were adjusted based to keep serum theophyl-
line levels within a predefined range in nine studies [21,23–26,28,30,32,34] In two studies
[28,32] serum theophylline levels were factored into loading dose calculations.
Quantitative Synthesis
Quantitative synthesis was possible for studies comparing aminophylline to placebo in the
domains of resolution of symptoms, time until discharge criteria are met, and length of stay
(Fig 3). Meta analysis was not possible for studies comparing aminophylline to β2 agonists due
to incomplete outcome reporting.
Table 1. Results of RCTs comparing aminophylline to placebo *Loading doses altered based on the results of TDM. ASS asthma severity score,














n = 163 (81 vs 82)
10 0.7 to 1.1 Not reported Not reported Not reported 2.87 days vs.
2.69 days in
p = 0.53
Higher rates of nausea and
vomiting but not headache,
irritability and tremor
Needleman 1995
[21] n = 42 (22 vs
20)
6–8 0.8 to 1 Change in ASS 6.96
±1.65 vs 7.00±1.73 to
3.05±3.25 vs 2.38±2.19
[p = 0.482]
Not reported 52.3±32.3 hours
vs 48.2±26.6
hours p = 0.654
Not measured Not reported
Strauss 1994 [29]
n = 31 (14 vs 17)
7 0.75 to 1.2 Not reported Not reported Not reported 2.58±1.5 days
vs 2.33±1.3
days p>0.2
Higher rates of side effects
in intervention vs
aminophylline group 6/14
(43%) vs 1/17 (6%) in
control p<0.05
Ream 2001 [22]
n = 47 (23 vs 24)
7 0.5–0.8 Time to reach CAS<3
18.6±12.0 h vs 31.1














[23], n = 38 (17 vs
19)
6 0.8 to 1.0 Clinical asthma score at
24 hours in intervention
vs placebo 2.05±1.61 vs
1.94±1.78 p = 0.8452




n = 29 (13 vs 16)
6 0.85 to 1.0 Time to reach asthma
score <2 in intervention
vs control 30.4±16.n vs
27.0±10.3 p = 0.51
Not reported 30.4±16.8h vs
27.0±10.3h
p = 0.51.




n = 60 (30 vs 30)





n = 21 (12 vs 9)
TDM* 0.8 to 1.0 Median CAS/PI at 36
hours 2.0 vs 2.0 p>0.05







n = 39 (19 vs 20)
5* 0.9 CAS 24 hours in
intervention vs control
2.0 vs 2.6 p>0.05
Not reported Not reported Not reported Higher rates of nausea and
emesis in theophylline group
p0.05 but not insomnia
p = 0.08
Vieira 2000 [33]
n = 43 (24 vs 19)
6 1.2 Time to reach Wood-
Downes score 2 12.5h
vs 14.6h in p = 0.13
Not reported Not reported 12.5h vs 14.6 h
p = 0.13
No serious adverse events
in either group
*Doses calculated based on the results of therapeutic drug monitoring. ASS asthma severity score, CAS/PI clinical asthma score/pulmonary index.
doi:10.1371/journal.pone.0159965.t001
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Primary Outcomes
1) Time until resolution of symptoms. Symptom resolution was reported in seven studies
comparing aminophylline to placebo. Asthma score after a given time was reported in four
studies [21,23,28,32] and time to reach a predefined asthma score was reported in three studies
[22,30,33]. Adequate reporting in two studies allowed quantitative data synthesis (Fig 3). All
four studies comparing aminophylline to β2 adrenergic agonist reported symptom resolution
as an outcome. This was reported as time to reach a predefined asthma score in one [36],











Actual Discharge Adverse effects
Wheeler 2005
[25] n = 40 (Am
n = 13, β2 n = 16,
both n = 11)
6.4 0.64 to
0.96









Not reported NS in the median number
of adverse effects, higher
incidence of nausea in
combined group
Roberts 2003 [34]
n = 44 (Am n = 26
β2 n = 18)
5 0.9 Change in ASS over 2
hours -1.19±1.3 vs
-1.11±1.7 p = 0.85





Time to discharge in
aminophylline vs.
salbutamol 57.3h±43.3
vs. 85.4h±56.0 p = 0.02
Adverse effects In
aminophylline group vs.
salbutamol 22.2% vs. 36%
p = 0.50
Singhi 2011 [35]
n = 100 (Am
n = 33, β2 n = 33,
MgSO4 n = 34)
5 0.9 number of participants
with improvement in
CAS at 1h4 am, ter,
5 vs. 5 p = 0.002
Not reported Not
measured
Not reported None in Mg group, 2
patients in terbutaline
group had hypokalaemia
and 9 in am group had
nausea/vomiting
Hambleton 1979
[27] n = 18
4 0.6 Change in asthma
score at 24 hours 4.5
vs 4.0 in p>0.05
Not reported Not reported Not reported Higher rates of
tachycardia in salbutamol
group
Am aminophylline, β2 beta 2 agonist, ASS asthma severity score, MgSO4 magnesium sulphate CAS/PI clinical asthma score/pulmonary index. Sizes of
intervention vs. control groups were not reported in Hambleton 1979
doi:10.1371/journal.pone.0159965.t002
Fig 3. Quantitative synthesis of studies comparing aminophylline to placebo.Dose Regimens: Digiulio 1993 6mg/
kg bolus 0.8–1.0mg/kg/h infusion, Ream 2001 7mg/kg bolus 0.5–0.8mg/kg/h infusion, Needleman 1995 6-8mg/kg bolus
0.8–1.0mg/kg/h infusion, Carter 1993 loading dose calculated on TDM infusion 0.8–1.0mg/kg/h, D’Aliva 2008 2 x 5mg/kg
bolus, Strauss 1994 7mg/kg/h bolus 0.75 to 1.2 infusion
doi:10.1371/journal.pone.0159965.g003
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change in asthma score in two [27,34] and the proportion of patients in each group achieving a
low asthma score in the remaining score [37].
There appeared to be no discernible relationship between aminophylline dosage and
improvement in symptoms. Although one study reported quicker improvement in asthma
score with a loading dose of 7mg/kg followed by an infusion of 0.5–0.65mg/kg/hr (time to
reach CAS3 in aminophylline vs placebo group 18.6±12.0h, n = 23 vs 31.1±20.1h, n = 24
[p = 0.0238]) [22], this finding is not replicated in studies using similar doses [21,30]. Intrave-
nous aminophylline at any dose was equally effective when compared to β2 adrenergic agonist
at improving symptoms.
2) Need for Mechanical ventilation. No studies comparing aminophylline to placebo
assessed effect of IV aminophylline against placebo, in non-intubated children, on the subse-
quent need for mechanical ventilation. One study comparing a 5mg/kg loading dose followed
by an infusion of 0.9mg/kg/h to β2 adrenergic agonist, found a that one subject in the aminoph-
ylline group and 2 in the β2 adrenergic agonist group required mechanical ventilation [p>0.05]
[34] however it is not possible to compare this finding with other doses given.
3) Mortality. There were no reported deaths in any study
Secondary outcomes
1) Time until discharge criteria are met. Time until discharge criteria are met was
reported in three studies comparing aminophylline to placebo, one using a 7mg/kg loading
dose followed by an infusion of 0.5–0.8mg/kg/hr [22] and one using a 6mg/kg loading dose fol-
lowed by an infusion rate of 0.85–1.0mg/kg/hr [30], and one adjusting loading and mainte-
nance doses based on age [21]. No studies reported a significant improvement in time until
discharge criteria are met with the use of intravenous aminophylline at any dose. One study
reported an improvement in the very small subset of patients who were intubated prior to
enrollment 74.8±15.4, n = 3 in theophylline group vs 189.3±59.8, n = 3 in control p = 0.0325
[22]. Three studies were included in quantitative data synthesis (Fig 3).
2) Actual Discharge. Length of stay was reported in five studies comparing aminophylline
to placebo [22,24,28,31,38] and one study comparing aminophylline to β2 adrenergic agonist
[34]. Four studies reported the number of days spent in hospital [22,24,28,38] one study reported
the number of hours spent in the paediatric emergency room, [31] and one study reported the
number of hours spent in hospital [34]. No statistically significant difference was observed in
shortening hospital length of stay at any dose of aminophylline when compared with placebo. A
loading dose of 5mg/kg followed by an infusion of 0.9mg/kg/h was shown to significantly shorten
hospital stay compared with β2 adrenergic agonist (57.3h±43.3, n = 26 vs 85.4h±56.0, n = 18
[p = 0.02]) [34]. Four studies were included in quantitative data synthesis (Fig 3).
3) Adverse effects. Adverse effects were compared in six studies comparing aminophylline
to placebo [23,24,28,30,32,38] and no studies comparing aminophylline to β2 adrenergic
agonist.
There appears to be a higher rate of adverse effects in participants receiving higher loading
doses. A significantly higher rate of adverse effects was reported in two studies using a loading
dose of 10mg/kg and 7mg/kg [24,26] but not in studies using loading doses between 5-6mg/kg
[22,23,30,33]. One study reported a higher rate of adverse effects in subjects receiving a loading
dose calculated using 500ml/kg X change in serum level formula [32].
Discussion
There is a lack of evidence on which to determine to most effective and safe intravenous dosage
of aminophylline for children suffering an acute exacerbation of asthma. There is weak
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evidence to suggest that loading doses above 7mg/kg result in a higher rate of nausea and vom-
iting. There is no evidence to indicate that adjustment of dose based on age or serum theophyl-
line levels increases the efficacy or safety of IV aminophylline.
No RCTs have directly compared dosing strategies for aminophylline when used for acute
asthma exacerbations in children. The indirect evidence from RCTs comparing aminophylline
with placebo demonstrates no clear relationship between dosage regimen, which varies across
studies, and clinical efficacy and safety. The majority of dosing strategies aim to achieve serum
theophylline levels within a predefined range, but this did not translate into clinical
improvement.
Forming dosing recommendations for IV aminophylline in children is complex as the drug
is used in a wide age range of children with highly variable pharmacokinetic properties.
Although efforts to account for this variability are reflected in dosing adjustments made for
age, weight and previous theophylline levels, it is unclear whether these adjustments play a sig-
nificant role in improving the clinical outcomes of children with acute asthma. Dosing strate-
gies based on evidence of clinical improvement are an important factor when comparing the
efficacy of intravenous bronchodilators for the treatment of childhood asthma. There is a need
for research linking the pharmacokinetic knowledge of theophylline, with clinically relevant
outcomes in acute asthma in children.
As no RCTs compare different aminophylline dosage in the treatment of childhood asthma
exacerbations, this review is hindered by its use of indirect evidence. Our quantitative analyses
are limited by the small sample sizes, varied dosing strategies and inconsistent outcome report-
ing across studies. This meta analysis is not able to provide additional information to improve
prescribing practices or guide future trial design. Furthermore, this review included studies
spanning a 32 year time period and intravenous theophylline and aminophylline (theophylline
with ethyldiamine) were considered together.
The optimal dosing of IV aminophylline in acute childhood asthma requires accurate
assessment of its efficacy and adverse effects. A recent survey of paediatric emergency depart-
ments in the British Isles has shown that over 95% of children receive the same loading dose
(5mg/kg) [39]. Though dosage guidelines are followed, the clinical outcomes of this strategy
are not clear. Prior to conducting RCTs comparing doses, we believe that it is important to
establish the clinical effectiveness of the currently recommended dose, to establish the level of
clinical improvement seen using validated asthma scores in children, and provide adverse effect
data. This will allow the paediatric asthma community to determine if the current benefit:risk
ratio of IV aminophylline is satisfactory, and whether RCTs with alternate doses (to improve
efficacy using higher doses, or avoid adverse effects using lower doses) are appropriate.
Conclusion
The currently recommended dosage strategy of intravenous aminophylline may not represent
the optimum safety and efficacy profile of the drug in childhood asthma exacerbations. There
is poor evidence that dosage adjustments based on age weight and previous serum theophylline
levels improve asthma outcomes in children. An investigation correlating dosage to clinically
relevant outcomes is needed to develop studies aiming to improve prescribing practices of
intravenous aminophylline.
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